Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567255 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects
A Phase 3 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,496
- Enrollment target
NCT00567255: Completed Phase 3 study, sponsored by Orexigen Therapeutics.
NCT00567255 is a Phase 3 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 1,496 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00567255, a Phase 3 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,496 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.
Interventions
- DRUG Placebo
- BEHAVIORAL Ancillary therapy
- DRUG Naltrexone SR 32 mg/bupropion SR 360 mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,496 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00567255 record still lists
NCT00567255 is an interventional study that assigns participants to a tested intervention. Its 1,496 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00567255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00567255 about?
NCT00567255 is a clinical study titled "A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects". The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.
What is the current status of trial NCT00567255?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,496 participants. The study started on 2007-12. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00567255?
The interventions under investigation include: Placebo (DRUG), Ancillary therapy (BEHAVIORAL), Naltrexone SR 32 mg/bupropion SR 360 mg/day (DRUG).
Who is sponsoring clinical trial NCT00567255?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00567255's enrollment target sits among peer trials
1,496 163rd of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia